Drug Database
EN

encephalitis inactivated vaccine

✓ Approved

Changchun Institute · 疫苗 · 疫苗

什么是 encephalitis inactivated vaccine?

encephalitis inactivated vaccine 是一种疫苗,由Changchun Institute研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

公司Changchun Institute
药物类别疫苗
给药途径Unknown
状态Approved

治疗适应症

encephalitis inactivated vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsTick-borne viral encephalitis✓ Approved

相关研究文献

PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →
PubMedFrontiers in public health2026-11-18

Characteristics of adverse events of inactivated quadrivalent influenza vaccine in healthy populations: a meta-analysis based on randomized controlled trials.

Kang Liuyang L, Yang Jing J, Cheng Jingru J, Tang Shaowen S et al.

Influenza constitutes a critical global public health issue, and quadrivalent inactivated influenza vaccine (QIV) is widely used, yet systematic analyses of its adverse events (AEs) remain lacking. This meta-analysis aimed to characterize AEs following QIV vaccination in healthy populations. We searched for randomized controlled trials (RCTs) of QIV vaccination in healthy populations, extracted AE data from QIV groups, pooled incidence rates, and compared the risks of AEs between QIV and trivalent influenza vaccine (TIV) using a random-effects model. Subgroup analyses, meta-regression, and sensitivity analyses were applied to explore heterogeneity and result robustness. Publication bias was evaluated utilizing Begg's and Egger's tests. A total of 29 studies published from 2008 to 2025 were included, involving 28,410 participants with 8,197 reported AEs in total. The overall incidence of AEs after QIV vaccination in healthy populations was 43% (95% CI: 31%-54%), with an incidence of 27% (95% CI: 18%-37%) for local AEs and 20% (95% CI: 14%-26%) for systemic AEs. The incidence of SAEs was 0.96%. The QIV group showed significantly elevated risks of overall and local AEs relative to TIV (P < 0.05), while no significant differences were detected in systemic AEs and SAEs between the two groups (P > 0.05). Heterogeneity was associated with study period, study region, AE collection duration, and vaccine origin. Sensitivity analyses and publication bias analyses confirmed result stability. This study summarizes AE incidence and features after QIV in healthy populations, supporting clinical vaccination and post-vaccination safety surveillance with exploratory data. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233388, identifier CRD420251233388.

PMID 43047547
阅读全文 →
PubMedAnnals of African medicine2026-11-18

Prevalence of Japanese Encephalitis in Pediatric Patients with Positive Vaccination History among Acute Encephalitis Syndrome Cases at a Tertiary Care Center in Ranchi, Jharkhand: A Retrospective Observational Cross sectional Study.

Zarrin Fauzia F, Jha Sunanda S, Sawez Md M, Kumar Anand A et al.

Acute encephalitis syndrome (AES) remains a leading cause of pediatric neuro-morbidity in India. Japanese Encephalitis (JE) is a major viral contributor. Despite mass immunization, breakthrough infections present an emerging public health challenge. To determine the prevalence of JE among vaccinated pediatric AES patients, evaluate real-world vaccine effectiveness, and identify risk factors for breakthrough infections. We conducted a single-center retrospective observational cross-sectional study at Rajendra Institute of Medical Sciences, Ranchi, analyzing 267 pediatric patients (aged 3-18 years) admitted with AES over 12 months. Diagnosis was confirmed using cerebrospinal fluid MAC-ELISA or serum MAC-ELISA for JE-specific IgM antibodies and brain magnetic resonance imaging. Among 267 enrolled cases, 189 (70.8%) had documented JE vaccination. JE positivity was significantly lower among vaccinated than unvaccinated children (24.3% vs. 46.2%; P < 0.001), representing a 47.4% relative reduction in JE prevalence among AES admissions. JE prevalence significantly increased with time elapsed since vaccination (14.3% at <1 year vs. 40.0% at >5 years; P = 0.012). In multivariable logistic regression, time since vaccination ≥3 years (adjusted odds ratios [aOR] = 2.84, 95% confidence interval [CI]: 1.24-6.51; P = 0.014), proximity to rice fields (<500 m) (aOR = 2.56, 95% CI: 1.02-6.42; P = 0.045), and monsoon season admission (aOR = 3.18, 95% CI: 1.35-7.48; P = 0.008) were independent risk factors for breakthrough infections. Vaccinated JE-positive cases had higher mortality (21.7% vs. 10.5%; P = 0.045) and neurological sequelae rates (52.2% vs. 33.6%; P = 0.026) than vaccinated JE-negative controls. Among hospitalized pediatric AES admissions, a notable hospital-based breakthrough prevalence of 24.3% was observed, driven primarily by waning immunity over time and intense environmental exposure. Implementing booster schedules at -year intervals and integrated vector control are urgently needed.

PMID 43049156
阅读全文 →
PubMedInfection & chemotherapy2026-11-18

Development of an Interferon-γ ELISPOT Assay to Assess Varicella-Zoster Virus-Specific Cell-Mediated Immunity in Children.

Han Mi Seon MS, Choi Eun Hwa EH

Cell-mediated immunity (CMI) is fundamental in the prevention and control of varicella-zoster virus (VZV) infection and reactivation. This study aimed to develop and optimize a standardized interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay to precisely quantify VZV-specific T-cell responses in pediatric populations. Peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood of seven healthy adult and six pediatric donors, collected in heparinized tubes. An ultraviolet (UV)-inactivated varicella vaccine was utilized as the VZV-specific antigen. PBMCs were incubated on 96-well plates pre-coated with anti-human IFN-γ monoclonal antibodies. Secreted IFN-γ was detected using biotinylated anti-human IFN-γ antibodies, streptavidin-horseradish peroxidase, and chromogen substrate. Spot-forming cells (SFCs) were enumerated using and ImmunoSpot Image Analyzer system. Various experimental parameters, including antigen dilution, PBMC density, and the impact of cryopreservation, were evaluated in triplicate. UV irradiation for 60 minutes completely abolished VZV replication while preserving stimulatory activity equivalent to that of the live-attenuated virus. Optimal VZV-specific responses were achieved at an antigen dilution of 1:25. Titration of PBMC concentrations demonstrated that a density of 1 × 10⁶ cells/well yielded the most robust and consistent SFC counts. Furthermore, IFN-γ ELISPOT responses from cryopreserved PBMCs were equivalent to those from freshly isolated cells, confirming the reliability of using frozen samples. In the pediatric cohort, the assay successfully detected VZV-specific CMI by utilizing a higher density of PBMCs per mL of whole blood. The optimized IFN-γ ELISPOT assay established in this study provides a sensitive, reproducible, and safe method for monitoring VZV-specific CMI. This standardized protocol is well-suited for evaluating vaccine efficacy and assessing disease susceptibility in immunocompromised children in clinical settings.

PMID 43046813
阅读全文 →
PubMedEpileptic disorders : international epilepsy journal with videotape2026-11-18

Extreme delta brush as an ictal pattern in anti-NMDA receptor encephalitis.

Casson Nicole E NE, Moser Filho Humberto L HL, Van Winssen Christine M CM, Hirsch Lawrence J LJ et al.

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis frequently presents with psychiatric symptoms, seizures, dyskinesias, autonomic instability, and characteristic electroencephalographic (EEG) abnormalities including extreme delta brush (EDB). Differentiating epileptic from non-epileptic dyskinetic movements remains challenging, and the ictal versus interictal nature of EDB remains incompletely understood. In this case, a 22-year-old man developed neuropsychiatric symptoms progressing to hallucinations, confusion, abnormal speech, dyskinetic movements, and generalized tonic-clonic seizures. Brain MRI was unremarkable. Cerebrospinal fluid demonstrated positive anti-NMDAR antibodies. Continuous EEG initially showed diffuse slowing without correlation to dyskinetic movements of grimacing, jaw thrusting, and limb posturing. During treatment, abundant stereotyped episodes of facial pulling with rhythmic lip twitching emerged and were found on EEG to have an ictal correlate consistent with focal motor status epilepticus. Following reduction in ictal burden, EEG demonstrated a striking pattern of highly stereotyped right jaw movement and right arm internal rotation synchronized to complexes of midline beta-gamma activity overriding each delta wave peak, qualifying as a definite EDB pattern with clinical correlate to each EDB complex. Thus, in this case, EDB was an ictal pattern. This case illustrates the overlap between seizures and dyskinesias in anti-NMDAR encephalitis and highlights characteristic EEG findings including the EDB pattern. Unlike classic descriptions of EDB as a non-ictal EEG biomarker of severe anti-NMDAR encephalitis, this patient demonstrated clinical motor events time-locked to each EDB complex, supporting the possibility that EDB patterns represent ictal phenomena, at least in some cases such as this one. Continuous EEG monitoring is essential to distinguish electroclinical seizures from dyskinesias and may provide further insight into the potentially ictal significance of EDB.

PMID 43049564
阅读全文 →
PubMedBioinformatics and biology insights2026-11-18

Formulation of a Novel NS5A- and NS5B-Based Chimeric Vaccine Against Hepatitis C Virus: An Artificial Intelligence-Supported Approach.

Niknam Maryam M, Zohrabzadeh Maryam M, Hahashempour Ava A, Honari Jahromi Ali A et al.

We aimed to design a multiepitope vaccine against hepatitis C virus (HCV) with the potential to elicit broad protective immunity against diverse HCV genotypes through computational design.Method: One hundred sequences of the most widespread subtypes of HCV were retrieved from the Los Alamos National Laboratory database, and consensus sequences of the NS5A and NS5B proteins were generated to construct an efficient vaccine for human use. Numerous B-cell lymphocyte, cytotoxic T-lymphocyte and helper T-lymphocyte epitopes located in the conserved domains of HCV proteins and similar in human and mouse alleles were evaluated criteria for use in the vaccine construct. Population coverage analysis identified that substantial parts of the worldwide population carry epitopes and their corresponding alleles within their genome, which confirms that the vaccine candidate is an effective agent against this lethal disease. Codon optimization and in silico cloning of eukaryotic and prokaryotic vectors validated the strong expression of the vaccine construct in the host systems. Molecular docking analysis revealed favorable binding affinities between the vaccine construct and toll-like receptors, which confirmed the vaccine's capacity to induce robust and stable immune responses against the hepatitis C virus. We incorporated new bioinformatic methods to design multiepitope vaccine against HCV. The development of a vaccine targeting multi genotypes of HCV could potentially provide for long-term protection against infection and may mitigate the risk of drug resistance across various genotypes and subtypes. Current research emphasizes the need for a vaccine that can elicit comprehensive immune responses, including both neutralizing antibodies and T-cell responses, to effectively address the genetic diversity of the virus. Future experimental studies are essential to validate predicted immunogenicity, structural stability, and protective efficacy before clinical consideration.

PMID 43047676
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多encephalitis inactivated vaccine